



For release: September 6, 2018

Ac2orn Congratulates Novartis on their Approval of Kymriah

Ac2orn congratulates Novartis on the approval of their chimeric antigen receptor T cell (CAR-T) therapy, Kymriah (tisagenlecleucel/CTL019), by Health Canada. Kymriah is the first CAR-T cell therapy to receive approval in Canada.

Vancouver, British Columbia -

Advocacy for Canadian Childhood Oncology Research Network, Ac2orn, congratulates Novartis on the approval of the first chimeric antigen receptor T cell (CAR-T) therapy, Kymriah (tisagenlecleucel/CTL019), by Health Canada. Kymriah is changing the landscape of cancer treatment for children, adolescents and young adults with relapsed and refractory acute lymphoblastic leukemia (ALL). Kymriah is a personalized therapy that uses the patient's own T cells to find and kill cancer cells – it heralds a new era of targeted cancer treatment beyond traditional chemotherapy, radiation or surgery.

Ac2orn was pleased to work with the Leukemia and Lymphoma Society of Canada (LLSC) and Ontario Parents Advocating for Children with Cancer (OPACC) on the patient input submission for the pan Canadian Oncology Drug Review (pCODR) application for Kymriah. The patient input submission is one part of the pCODR process which ensure that the patient voice is included in the decision making process when drugs and treatments are approved by Health Canada. Patient experiences and stories were collected from families across Canada to understand their journey with ALL and CAR T-cell therapy to write the patient input submission.

“It's remarkable to see the CAR T therapy transform my son's health. In one month he went from being very ill to his old self.” – Kymriah Pediatric Patient Family

About Ac2orn:

Advocacy for Canadian Childhood Research Network, Ac2orn, is committed to advocating for Canadian researchers as they implement the dream of curing childhood, adolescent and young adult cancers through translational research and effective treatments. Ac2orn is a national organization made up of childhood, adolescent and young adult cancer families and survivors who are dedicated to breaking down barriers and building bridges in cancer research. Ac2orn was formed in 2014. <http://www.cureseforourkids.com>

For more information, please contact:

Patrick Sullivan, Ac2orn Executive
patrick@ac2orn.com, 604.764.7087

Antonia Palmer, Ac2orn Executive
antonia@ac2orn.com, 416.315.7576